Opaque Pricing Could Protect Europe From US Policy
Executive Summary
Obscure drug pricing in Europe could help minimize an “access threat” posed by US pricing policies.
You may also be interested in...
Presidential Arm Twisting: Drug Pricing Order Would Advance International Benchmarks Unless Industry Offers Alternative
Industry has 30 days to come up with a better idea that would “end foreign free riding” and close the gap between drug prices in the US and abroad, President Trump says. Administration also wants to revive rebate reform.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.